Shire (LON:SHP)‘s stock had its “outperform” rating reaffirmed by research analysts at BNP Paribas in a report issued on Tuesday. They currently have a GBX 4,700 ($63.74) price target on the biopharmaceutical company’s stock. BNP Paribas’ price objective suggests a potential upside of 36.17% from the company’s previous close.
Several other research analysts have also weighed in on the stock. Barclays reissued an “equal weight” rating and set a GBX 4,000 ($54.24) price objective on shares of Shire in a report on Monday, October 30th. Shore Capital reissued a “buy” rating on shares of Shire in a report on Thursday, October 26th. Goldman Sachs Group reissued a “conviction-buy” rating on shares of Shire in a report on Tuesday, October 17th. Morgan Stanley decreased their price objective on shares of Shire from GBX 5,800 ($78.65) to GBX 5,700 ($77.30) and set an “overweight” rating for the company in a report on Thursday, October 12th. Finally, Citigroup reissued a “buy” rating and set a GBX 5,500 ($74.59) price objective on shares of Shire in a report on Friday, December 8th. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of GBX 5,082.35 ($68.92).
Shares of Shire (LON:SHP) traded down GBX 48.50 ($0.66) during mid-day trading on Tuesday, reaching GBX 3,451.50 ($46.81). 3,750,000 shares of the company’s stock traded hands, compared to its average volume of 2,410,000. The firm has a market cap of $31,400.00 and a price-to-earnings ratio of 2,696.48. Shire has a 52 week low of GBX 3,403.50 ($46.16) and a 52 week high of GBX 5,067 ($68.71).
In other news, insider Dominic Blakemore acquired 165 shares of the business’s stock in a transaction that occurred on Tuesday, December 19th. The shares were purchased at an average cost of GBX 3,790 ($51.40) per share, for a total transaction of £6,253.50 ($8,480.47).
WARNING: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/18/shire-shp-stock-rating-reaffirmed-by-bnp-paribas.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.